VCYT Quote, Financials, Valuation and Earnings

Hypha Labs, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of --. Veracyte, Inc.'s return on equity of 2.52% beat Hypha Labs, Inc.'s return on equity of --.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 33.78%. On the other hand Hypha Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Veracyte, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe Veracyte, Inc. is more attractive than Hypha Labs, Inc..

Veracyte, Inc. has a beta of 1.913, which suggesting that the stock is 91.288% more volatile than S&P 500. In comparison Hypha Labs, Inc. has a beta of 1.232, suggesting its more volatile than the S&P 500 by 23.248%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hypha Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. Hypha Labs, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than Hypha Labs, Inc. quarterly revenues of --. Veracyte, Inc.'s net income of $19.1M is higher than Hypha Labs, Inc.'s net income of -$521.6K. Notably, Veracyte, Inc.'s price-to-earnings ratio is 93.86x while Hypha Labs, Inc.'s PE ratio is 4.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 5.72x versus 1.16x for Hypha Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Interpace Biosciences, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of 11.55%. Veracyte, Inc.'s return on equity of 2.52% beat Interpace Biosciences, Inc.'s return on equity of --.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 33.78%. On the other hand Interpace Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 494.6%. Given that Interpace Biosciences, Inc. has higher upside potential than Veracyte, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.913, which suggesting that the stock is 91.288% more volatile than S&P 500. In comparison Interpace Biosciences, Inc. has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.457%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Interpace Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. Interpace Biosciences, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than Interpace Biosciences, Inc. quarterly revenues of $8.8M. Veracyte, Inc.'s net income of $19.1M is higher than Interpace Biosciences, Inc.'s net income of $1M. Notably, Veracyte, Inc.'s price-to-earnings ratio is 93.86x while Interpace Biosciences, Inc.'s PE ratio is 6.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 5.72x versus 0.71x for Interpace Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of 16.21%. Veracyte, Inc.'s return on equity of 2.52% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.23%.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 33.78%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $666.46 which suggests that it could grow by 30.44%. Given that Veracyte, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Veracyte, Inc. is more attractive than Thermo Fisher Scientific, Inc..

Veracyte, Inc. has a beta of 1.913, which suggesting that the stock is 91.288% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.928, suggesting its less volatile than the S&P 500 by 7.166%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.34% to investors and pays a quarterly dividend of $0.43 per share. Veracyte, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.7% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Veracyte, Inc. quarterly revenues are $131.9M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $12.2B. Veracyte, Inc.'s net income of $19.1M is lower than Thermo Fisher Scientific, Inc.'s net income of $2B. Notably, Veracyte, Inc.'s price-to-earnings ratio is 93.86x while Thermo Fisher Scientific, Inc.'s PE ratio is 28.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 5.72x versus 4.33x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -2.87%. Veracyte, Inc.'s return on equity of 2.52% beat XWELL, Inc.'s return on equity of -224.93%.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 33.78%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1743.08%. Given that XWELL, Inc. has higher upside potential than Veracyte, Inc., analysts believe XWELL, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.913, which suggesting that the stock is 91.288% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.511, suggesting its more volatile than the S&P 500 by 51.09%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Veracyte, Inc.'s net income of $19.1M is higher than XWELL, Inc.'s net income of -$211K. Notably, Veracyte, Inc.'s price-to-earnings ratio is 93.86x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 5.72x versus 0.07x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.